To Evaluate the Efficacy and Safety of Aspherical Soft Contact Lens in Myopia Control

Overview

The objective of this study is to demonstrate that the Ticon Aspherical Daily Disposable Soft Contact Lens could retard myopia progress in youth

Full Title of Study: “A Prospective Randomized Control Study to Evaluate the Effect of Ticon Aspherical Daily Disposable Soft Contact Lens on Myopia Control”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 12, 2018

Detailed Description

This study is designed as a prospective, multicenter, randomized, double blinded, controlled, paired-eye comparison study. At least 60 evaluable subjects with myopia progression ≧ 0.75 D in the past 12 months will be recruited from 2 study sites. The experimental soft contact lens with aspherical design (Ticon Aspherical) will be randomly assigned to either the right eye or the left eye of the subject , then the fellow eye will be assigned a control lens with a single vision distance (SVD) soft contact lens (Ticon). Both lenses will be worn at least 8 hours a day, 5 days a week for 1 year. All lenses will be replaced every day. Brief assessment of the clinical findings will be followed up for one year at 1 day, 1 week, 1, 3, 6, 9, 12 months upon allocation. The primary efficacy outcome is change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction over 12 months. The secondary outcome is change in axial eye length (AXL) measured over 12 months. The secondary outcome measure is used to corroborate any changes in SER

Interventions

  • Device: soft contact lens

Arms, Groups and Cohorts

  • Experimental: Ticon Aspherical Daily Disposable Soft Contact Lens
    • The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
  • Placebo Comparator: Ticon Daily Soft Contact Lens
    • The subject will be requested to wear lens 8 hours a day, 5 days a week at least. The contact lens will be worn and replaced every day. All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.

Clinical Trial Outcome Measures

Primary Measures

  • Spherical Equivalent Refraction (SER)
    • Time Frame: 12 months
    • The change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction over 12 months.

Secondary Measures

  • Axial Eye Length (AXL)
    • Time Frame: 12 months
    • The change in axial eye length (AXL) measured over 12 months. Axial length is measured after cycloplegia using optical biometry.

Participating in This Clinical Trial

Inclusion Criteria

  • Myopia (SE) between -1.00D to -8.00D – Astigmatism less than or equal to 1.75D – Myopia progression ≧0.75 D in the past 12 months – Best Corrected Visual Acuity (BCVA): 0.9 Snellen or better – Willingness to wear contact lens constantly – Availability for follow-up for at least 1 year – Parent's understanding and acceptance – have an acceptable surrogate capable of giving legally authorized consent on behalf of the subject Exclusion Criteria:

  • Anisometropia greater than 2.00D – Presence of ocular disease preventing wear of contact lens – Severe ocular or systemic allergies – Taking any medication that might have an impact on contact lens wear or that might influence the outcome of the clinical trial – Ocular or systemic condition that might affect refractive development – Atropine/Pirenzepine treatment for myopia control in the past 1 month – Prior use of Ortho-K lenses – Dry eye with Schimer Test (basal secretion test) < 5mm/5min or other physical condition that would contraindicate contact lens wear

Gender Eligibility: All

Minimum Age: 9 Years

Maximum Age: 15 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • APP Vision Care Inc.
  • Collaborator
    • National Taiwan University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tzu-Hsun Tsai, M.D., Study Chair, National Taiwan University Hospital
    • Elizabeth P Shen, M.D., Principal Investigator, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
    • Hsiao-Sang Chu, M.D., Principal Investigator, National Taiwan University Hospital
    • Han-Chih Cheng, M.D., Principal Investigator, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.